May 17, 2023 / 01:30PM GMT
Luca Issi - RBC Capital Markets - Analyst
Yeah. Luca Issi, senior biotech analyst here at RBC Capital Market. And today is our great privilege to have Sangamo Therapeutics with us for a fireside chat. Representing the company, we have Sandy Macrae, Chief Executive Officer. Sandy, thanks so much for joining us. How are you doing today?
Sandy Macrae - Sangamo Therapeutics, Inc. - CEO
It's my pleasure, Luca. Great to be here.
Questions and Answers:
Luca Issi - RBC Capital Markets - AnalystFantastic. We have a long list of questions here, but maybe before we talk about individual program, it will be great if you can just talk big picture about what progress has the organization made over the last few months, and most importantly, what's ahead of here for Sangamo?
Sandy Macrae - Sangamo Therapeutics, Inc. - CEO
So we're making great progress. Sangamo is a fascinating company. We have three things that are in late-phase development with our friends at Pfizer, where we're
Trustpilot
